JERUSALEM , Nov. 12, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three and nine months ended September ...
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the fourth quarter and year ended December 31, 2019 and provides a corporate update.
Investors need to pay close attention to Intec Pharma (NTEC) stock based on the movements in the options market lately.
New Strong Buy Stocks for May 4th
Canopy Growth's (CGC) recent acquisition of European companies will help it expand its production footprint into one of the most promising international regions.
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today provides a business and clinical update on its development programs with the Company's proprietary oral drug delivery system, the Accordion Pill® platform, in a Letter to Shareholders. The full text of the letter is below.
In addition, the Company granted the underwriter a 30-day option to purchase up to an additional 2,437,500 ordinary shares and/or warrants to purchase up to 2,437,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The Company expects to receive gross proceeds of $6.5 million from the offering.
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the Jefferies Virtual Healthcare Conference.
JERUSALEM, Nov. 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that Company management will participate in the Jefferies London Healthcare Conference. Mr. Meckler's presentation will be webcast live and will be accessible through the Events section of Intec Pharma's website at www.intecpharma.com, where it will also be archived for a period of time.
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in March.
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will be participating in the 12th Annual LD Micro Main Event investor conference.
Fort Campbell soldiers return to Kentucky after deployment to NYC, New Mexico governor blocks reopening of popular drive-in, and more
Diarrhea caused by Escherichia coli in calves is an important problem in terms of survivability, productivity and treatment costs. In this study, 88 of 150 diarrheic animals tested positive for E. coli. Of these, 54 samples had mixed infection with other bact…
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0 million with Aspire Capital Fund, LLC ("Aspire Capital"), a Chicago-based institutional investor. Under the terms of the Agreement, Aspire Capital is committed to purchase up to $10.0 million of Intec Pharma's ordinary shares over a 30-month period extending into 2022, subject to certain terms and conditions. There are no warrants, derivatives, or other share classes associated with this agreement. Proceeds from the Agreement will be used to fund the Company's research and development activites, for working capital and for general corporate purposes.
Intec has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 8,145,976 ordinary shares. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces the termination of the Feasibility and Option agreement with Novartis for the development of a custom-designed Accordion Pill® (AP) for a proprietary Novartis compound, despite the AP having met the technical and pharmacokinetic (PK) clinical specifications set forth by Novartis. Novartis, following an internal and revised commercial strategic assessment, advised Intec that this program no longer meets Novartis' mid to long-term strategic goals. Novartis agreed to pay Intec Pharma $1.5 million USD on conclusion of the program.
JERUSALEM, May 28, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the Jefferies Virtual Healthcare Conference. Jefferies Virtual Healthcare Conference Date: June 2 –…
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that it intends to offer and sell a combination of ordinary shares (or pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase ordinary shares in an underwritten public offering. In addition, the Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of ordinary shares and/or warrants at the public offering price, less underwriting discounts and commissions. All of the ordinary shares and warrants in the offering will be sold by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the first quarter ended March 31, 2020 and provides a corporate update.
JERUSALEM , Sept. 25, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters highlighting data from the Company's Phase 3 ...
JERUSALEM , Sept. 16, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters in support of the Company's Phase 3 clinical ...
JERUSALEM, May 11, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the first quarter ended March 31, 2020 and provides a corporate update. Highlights from the Quarter and Recent Weeks Anno…
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
JERUSALEM, Sept. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in September.